Abstract
The clinical correlates of reduced serotonin (5-HT) in Alzheimer's disease (AD) remain unknown. The hypothesis of this study was that altered central serotonergic activity is related to aggression in AD. Twenty-two institutionalized, nondepressed elderly (12 M/10 F, mean age ± SD: 82.2 ± 6.4) with probable AD, severe cognitive impairment (MMSE = 4.1 ± 4.7) and significant behavioral disturbance (Neuropsychiatric Inventory (NPI) score ⩾ 8) were studied. The prolactin (PRL) response to d,l-fenfluramine (60 mg p.o.) was used as an index of central serotonergic function. The NPI aggression score, NPI irritability score, and Behavioral Pathology in AD aggression score were positively correlated to prolactin concentrations following fenfluramine challenge (rS = .61, p = .003; rS = .53, p = .012; and rS = .47, p = .029 respectively). In addition, aggressive patients showed a greater mean PRL increase (% baseline) (215 ± 60, n = 11) than nonaggressive subjects (123 ± 54, n = 11) (p = .01, 2-tailed t-test). The change in PRL concentration depended on level of cognitive impairment (p = .0004) and the gender x aggression interaction (p = .015) with the overall regression model accounting for 74% of the variance (r = 0.86, F = 11.9, p = .0001). Female aggressive subjects with less cognitive impairment had the largest response to fenfluramine challenge. These results suggest a complex link between aggression in AD and central serotonergic dysfunction having interactions with gender and cognitive impairment.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Adolffson R, Gottfries CG, Roos BE, Winblad B . (1979): Changes in brain catecholamines in patients with dementia of Alzheimer type. Brit J Psychiat 135: 216–233
Alexopoulos GS, Abrams RC, Young RC, Shamoian CA . (1988): Cornell scale for depression in dementia. Biol Psychiatry 23: 271–284
American Psychiatric Association . (1994): Diagnostic and Statistical Manual of Mental Disorders. Washington, DC, American Psychiatric Association
Arai H, Kosaka K, Iiziku R . (1984): Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 43: 388–393
Auchus A, Bissey-Black C . (1997): Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiat Clin Neurosci 9: 591–593
Bergman I, Brane G, Gottfries CG, Jostell KG, Karlsson I, Svennerholm L . (1983): Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. Psychopharmacology (Berl) 80: 279–283
Burke WJ, Dewan V, Wengel SP, Roccaforte WH, Nadolny GC, Folks DG . (1997): The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry 12: 519–525
Burke WJ, Folks DG, Roccaforte WH, Wengel SP . (1994): Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of the Alzheimer type. Am J Geriatr Psychiatry 2: 352–354
Cantillon M, Brunswick R, Molina D, Bahro M . (1996): Buspirone vs. haloperidol. A double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 4: 263–267
Charney DS, Goodman WK, Price LH, Woods SW, Rassmussen SA, Heninger GR . (1988): Serotonin function in obsessive-compulsive disorder. Arch Gen Psychiatry 45: 177–185
Chen CPL-H, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, Jobst KA, Francis PT . (1996): Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 66: 1592–1598
Coccaro EF, Astill JL . (1990): Central serotonergic function in parasuicide. Prog Neuro-Psychopharmacol & Biol Psychiat 14: 663–674
Coccaro EF, Kavoussi RJ . (1997): Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 4: 1081–1088
Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL . (1997): Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Am J Psychiatry 154: 1430–1435
Cohen CA, Gold DP, Shulman KI, Wortley JT, Mcdonald G, Wargon M . (1993): Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 33: 714–720
Cohen-Mansfield J, Billig N . (1986): Agitated behaviors in the elderly I. A conceptual review. J Am Geriatr Soc 34: 711–721
Cohen-Mansfield J, Marx MS, Rosenthal AS . (1989): A description of agitation in a nursing home. J Gerontol 44: M77–M84
Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV . (1997): Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581–588
Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JAN . (1984): Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 43: 1574–1581
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J . (1994): The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308–2314
Cutler NR, Haxby J, Kay AD, Narang PK, Lesko LJ, Costa JL, Ninos M, Linnoila M, Potter WZ, Renfrew JW, Moore AM . (1985): Evaluation of zimeldine in Alzheimer's disease: cognitive and biochemical measures. Arch Neurol 42: 744–748
Dehlin O, Hedenrud B, Jansson P, Nörgård J . (1985): A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr Scand 71: 190–196
Dubovsky SL, Thomas M . (1995): Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 56: 38–48
Fishbein DH, Lozovsky D, Jaffe J . (1989): Impulsivity, aggression, and neuroendocrine responses to serotonergic stimulation in substance abusers. Biol Psychiatry 25: 1049–1066
Folstein MF, Folstein SE . (1975): “Mini-mental state” A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 12: 189–198
Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Ross Russell RW, Symon L . (1975): Cerebral blood flow in dementia. Arch Neurol 32: 632–637
Herrmann N, Eryavec G . (1993): Buspirone in the management of agitation and aggression associated with dementia. Am J Geriatric Psychiat 1: 249–253
Herrmann N, Lanctôt KL . (1997): From transmitters to treatment: The pharmacotherapy of behavioral disturbances in dementia. Can J Psychiatry 42: 51S–64S
Hyttel J . (1994): Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9: 19–26
Katona C, Hunter B, Bray J . (1998): A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriat Psychiat 13: 100–108
Lanctôt KL, Herrmann N, Eryavec G, van Reekum G, Naranjo CA . (2002): Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Ger Psychiatry 17: 531–541
Lanctôt KL, Herrmann N, Mazzotta P . (2001): Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 13: 5–21
Lawlor BA, Radcliffe J, Molchan SE, Martinez RA, Hill JL, Sunderland T . (1994): A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry 9: 55–59
Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL . (1989): Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. Arch Gen Psychiatry 46: 542–549
Linnoila VMI, Virkkunen M . (1992): Aggression, suicidality, and serotonin. J Clin Psychiatry 53: 46–51
Malone KM, Corbitt EM, Li S, Mann JJ . (1996): Prolactin response to fenfluramine and suicide attempt lethality in major depression. Br J Psychiatry 168: 324–329
Mann DMA, Yates PO . (1983): Serotonin nerve cells in Alzheimer's disease. J Neurol Neurosurg Psychiatry 46: 96–98
Markianos M, Lykouras L, Stefanis C . (1996): Prolactin and TSH responses to TRH and to ECT in pre-and postmenopausal women with major depression. Biol Psychiatry 40: 403–406
McBride PA, Tierney H, DeMeo M, Chen JS, Mann JJ . (1990): Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol Psychiatry 27: 1143–1155
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM . (1984): Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944
McLoughlin DM, Lucey JV, Dinan TG . (1994): Central serotonergic hyperresponsivity in late-onset Alzheimer's disease. Am J Psychiatry 151: 1701–1703
Mintzer J, Mintzer-Brawman O, Mirski DF, Unger R, Nietert P, Meeks A, Sampson R . (1998): Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation. Biol Psychiatry 44: 918–921
Nyth AL, Gottfries CG . (1990): The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Brit J Psychiatr 157: 894–901
O′Keane V, O′Hanlon M, Webb M, Dinan T . (1991): d-Fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin Endocrinol 34: 289–292
Olafsson K, Jorgensen S, Jensen HV, Bille A, Arup P, Andersen J . (1992): Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 85: 453–456
Palmer AM . (1996): Neurochemical studies of Alzheimer's disease. Neurodegeneration 5: 381–391
Palmer AM, Stratman GC, Procter AW, Bowen DM . (1988): Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 23: 616–620
Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, Marin R, Jacob NJ, Huber KA, Kastango KB, Chew ML . (2002): Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 159: 460–465
Pollock BG, Mulsant BH, Sweet R, Burgio LD, Kirshner MA, Shuster K, Rosen J . (1997): An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriat Psychiat 5: 70–78
Procter AW, Francis PT, Stratmann GC, Bowen DM . (1992): Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochemical Res 17: 917–922
Quattrone A, Tedeschi G, Aguglia U, Scopacasa F, Di Renzo GF, Annunziato L . (1983): Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine. Br J Clin Pharmacol 16: 471–475
Raskind MA . (1993): Geriatric psychopharmacology: Management of late-life depression and the non-cognitive behavioral disturbances of Alzheimer's disease. In DL Dunner (ed), The Psychiatric Clinics of North America. Psychopharmacology II, Philadelphia, W.B. Saunders Company, pp 815–827
Reisberg B . (1988): Functional assessment staging (FAST). Psychopharmacol Bull 24: 653–659
Risch SC, Kalin NH, Murphy DL . (1981): Pharmacological challenge strategies: implications for neurochemical mechanisms in affective disorders and treatment approaches. J Clin Psychopahrmacol 1: 238–243
Sclan SG, Saillon A, Franssen E, Hugonot-Diener L, Saillon A, Reisberg B . (1996): The behavior pathology in Alzheimer's disease rating scale (BEHAVE-AD): reliability and analysis of symptom category scores. Int J Geriat Psychiat 11: 819–830
Siever LJ, Kahn RS, Lawlor BA, Trestman RL, Lawrence TL, Coccaro EF . (1991): II. Critical issues in defining the role of serotonin in psychiatric disorders. Pharmacol Rev 43: 509–525
Sultzer DL, Gray I, Gunay I, Berisford A, Mahler ME . (1997): A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 5: 60–69
Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesaña-Diaz E . (1997): A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitryiptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38: 246–252
van Praag HM . (1991): Serotonergic dysfunction and aggression control. Psychol Med 21: 15–19
Ware CJG, Fairburn CG, Hope RA . (1990): A community-based study of aggressive behaviour in dementia. Int J Geriatr Psychiatry 5: 337–342
Yamamoto T, Hirano A . (1985): Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann Neurol 17: 573–577
Acknowledgements
This study was supported by Physicians' Services Incorporated Foundation. Dr. Lanctôt was supported by the Alzheimer Society of Canada Research Program. Dr. Lanctôt and Dr. van Reekum are supported by the Kunin-Lunenfeld Applied Research Unit.
The authors gratefully acknowledge the assistance of Dr. V. Ozdemir, Dr. R.W. Shulman, Ms. R. Croxford, and Ms. K.E. Bremner.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lanctôt, K., Herrmann, N., Eryavec, G. et al. Central Serotonergic Activity is Related to the Aggressive Behaviors of Alzheimer's Disease. Neuropsychopharmacol 27, 646–654 (2002). https://doi.org/10.1016/S0893-133X(02)00339-1
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(02)00339-1
Keywords
This article is cited by
-
Neuropsychiatric Disorders in Dementia: Mechanisms of Development and Approaches to Correction
Neuroscience and Behavioral Physiology (2019)
-
Probleemgedrag, wat doe je eraan?
Bijblijven (2009)
